| First Author | Schmitt CA | Year | 2002 |
| Journal | Cancer Cell | Volume | 1 |
| Issue | 3 | Pages | 289-98 |
| PubMed ID | 12086865 | Mgi Jnum | J:77133 |
| Mgi Id | MGI:2181091 | Doi | 10.1016/s1535-6108(02)00047-8 |
| Citation | Schmitt CA, et al. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1(3):289-98 |
| abstractText | Although the p53 tumor suppressor acts in a plethora of processes that influence cellular proliferation and survival, it remains unclear which p53 functions are essential for tumor suppression and, as a consequence, are selected against during tumor development. Using a mouse model harboring primary, genetically modified myc-driven lymphomas, we show that disruption of apoptosis downstream of p53 by Bcl2 or a dominant-negative caspase 9 confers-like p53 loss-a selective advantage, and completely alleviates pressure to inactivate p53 during lymphomagenesis. Despite their p53-null-like aggressive phenotype, apoptosis-defective lymphomas that retain intact p53 genes do not display the checkpoint defects and gross aneuploidy that are characteristic of p53 mutant tumors. Therefore, apoptosis is the only p53 function selected against during lymphoma development, whereas defective cell-cycle checkpoints and aneuploidy are mere byproducts of p53 loss. |
